Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 26;13(15):3750.
doi: 10.3390/cancers13153750.

Glioblastoma: Emerging Treatments and Novel Trial Designs

Vincenzo Di Nunno  1 , Enrico Franceschi  1 , Alicia Tosoni  1 , Lidia Gatto  1 , Raffaele Lodi  2 , Stefania Bartolini  1 , Alba Ariela Brandes  1
Affiliations
Review

Glioblastoma: Emerging Treatments and Novel Trial Designs

Vincenzo Di Nunno et al. Cancers (Basel). .

Abstract

Management of glioblastoma is a clinical challenge since very few systemic treatments have shown clinical efficacy in recurrent disease. Thanks to an increased knowledge of the biological and molecular mechanisms related to disease progression and growth, promising novel treatment strategies are emerging. The expanding availability of innovative compounds requires the design of a new generation of clinical trials, testing experimental compounds in a short time and tailoring the sample cohort based on molecular and clinical behaviors. In this review, we focused our attention on the assessment of promising novel treatment approaches, discussing novel trial design and possible future fields of development in this setting.

Keywords: GBM; glioblastoma; new trial design; newly diagnosed glioblastoma; recurrent glioblastoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Phase 0 study overall design.
See this image and copyright information in PMC

References

    1. Ostrom Q.T., Cioffi G., Gittleman H., Patil N., Waite K., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016. Neuro Oncol. 2019;21:v1–v100. doi: 10.1093/neuonc/noz150. - DOI - PMC - PubMed
    1. Wen P.Y., Weller M., Lee E.Q., Alexander B.M., Barnholtz-Sloan J.S., Barthel F.P., Batchelor T.T., Bindra R.S., Chang S.M., Chiocca E.A., et al. Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020;22:1073–1113. doi: 10.1093/neuonc/noaa106. - DOI - PMC - PubMed
    1. Brat D.J., Aldape K., Colman H., Figrarella-Branger D., Fuller G.N., Giannini C., Holland E.C., Jenkins R.B., Kleinschmidt-DeMasters B., Komori T., et al. cIMPACT-NOW update 5: Recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol. 2020;139:603–608. doi: 10.1007/s00401-020-02127-9. - DOI - PMC - PubMed
    1. Brat D.J., Aldape K., Colman H., Holland E.C., Louis D.N., Jenkins R.B., Kleinschmidt-DeMasters B.K., Perry A., Reifenberger G., Stupp R., et al. cIMPACT-NOW update 3: Recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol. 2018;136:805–810. doi: 10.1007/s00401-018-1913-0. - DOI - PMC - PubMed
    1. Louis D.N., Wesseling P., Aldape K., Brat D.J., Capper D., Cree I.A., Eberhart C., Figarella-Branger D., Fouladi M., Fuller G.N., et al. cIMPACT-NOW update 6: New entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol. 2020;30:844–856. doi: 10.1111/bpa.12832. - DOI - PMC - PubMed

LinkOut - more resources